Tobin Juvenal Sells 17,310 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 17,310 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $29.31, for a total transaction of $507,356.10. Following the transaction, the insider owned 80,725 shares of the company’s stock, valued at $2,366,049.75. This trade represents a 17.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of CSTL opened at $30.40 on Thursday. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28. The business has a 50-day simple moving average of $23.38 and a two-hundred day simple moving average of $26.23. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The stock has a market cap of $928.72 million, a PE ratio of -46.06 and a beta of 0.98.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Analysts anticipate that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Trending Headlines about Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The revised target indicates substantial potential upside and reflects confidence in Castle Biosciences’ diagnostic-testing growth outlook. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results exceeded expectations, with revenue of $99.86 million versus the $86.23 million analyst consensus and a loss of $0.07 per share versus expectations for a $0.41 loss. The results support the case for improving operating performance, although the company remains unprofitable.
• Neutral Sentiment: Recent coverage highlighted developments involving Castle Biosciences’ diagnostics business, but the available details do not indicate whether the update will materially affect revenue, earnings or reimbursement expectations. Castle Biosciences diagnostics update
• Negative Sentiment: Multiple insiders disclosed stock sales totaling approximately $1.68 million. Derek J. Maetzold sold 28,646 shares, COO Kristen M. Oelschlager sold 8,586 shares, and Tobin W. Juvenal sold 19,040 shares in transactions conducted from July 31 through August 3. The sales reduced their holdings and may weigh on investor sentiment, particularly after the stock’s recent strength. However, all reported transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal than discretionary sales. Castle Biosciences insider sales filing

Analyst Ratings Changes

A number of equities research analysts have weighed in on CSTL shares. Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, April 20th. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a research note on Friday, May 29th. Roth Capital began coverage on shares of Castle Biosciences in a report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target on the stock. BTIG Research boosted their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. RTW Investments LP acquired a new stake in shares of Castle Biosciences during the 4th quarter worth approximately $82,283,000. Summit Partners Public Asset Management LLC lifted its position in shares of Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares during the period. Eventide Asset Management LLC bought a new position in Castle Biosciences during the fourth quarter worth $11,864,000. SG Americas Securities LLC boosted its stake in Castle Biosciences by 1,051.8% during the first quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock worth $6,012,000 after acquiring an additional 223,624 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Castle Biosciences in the fourth quarter worth $8,502,000. 92.60% of the stock is owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.